Drug

Isoproterenol (Isuprel)

Non-selective beta-agonist we use to provoke arrhythmias, unmask dormant PV conduction, and tease out latent triggers.

Indication
Arrhythmia provocation, PV reconnection testing, and bradycardia rescue
Typical dose
Infusion 1–20 mcg/min titrated to HR or arrhythmia induction

Why we use it

Isoproterenol is a synthetic catecholamine that hits beta-1 and beta-2 receptors with essentially no alpha activity. The result: increased heart rate, increased contractility, and arteriolar vasodilation. In the EP lab we exploit two things — sinus rate acceleration to bring out otherwise dormant arrhythmias, and dropping AV-node refractoriness to make supraventricular re-entry circuits easier to trigger.

Indication in the lab

  • SVT induction when programmed stimulation alone fails to initiate the clinical tachycardia
  • PV reconnection testing after pulmonary vein isolation — does a dormant connection light up under adrenergic drive?
  • Trigger mapping in AF ablation — non-PV triggers from coronary sinus, SVC, LAA may surface only on Iso
  • Idiopathic / outflow tract VT and PVC ablation when ectopy is sparse at baseline
  • Inappropriate sinus tachycardia / POTS testing
  • Temporary chronotropic support for severe bradycardia when pacing isn’t immediately available (rare in EP, more a crash-room use)

Dose and route

  • Standard provocation: start 1–2 mcg/min, titrate up.
  • High-dose challenge: 20 mcg/min for 3–5 minutes after PV isolation is a common protocol.
  • Maintenance for trigger mapping: 4–10 mcg/min, often paired with burst pacing.
  • Given as a continuous IV infusion via pump, ideally through a central line or large peripheral with a clean carrier.

Dilution matters — every lab has a standard concentration (commonly 2 mg in 250 mL D5W = 8 mcg/mL). Confirm with the bag label before starting.

Onset and duration

  • Onset: within 1–2 minutes of starting the infusion.
  • Steady-state: 5–10 minutes at a given rate.
  • Offset: drug effect dissipates within 5–10 minutes of stopping; useful when we need to “reset” between provocation runs.

Monitoring

  • Continuous ECG with rhythm strip running
  • Continuous arterial BP (cuff if no A-line)
  • SpO2 and EtCO2
  • Watch for the expected drop in diastolic BP — coronary perfusion lives there
  • Document HR, BP, rhythm at baseline, at each titration step, and when arrhythmia inducts

Side effects to watch for

  • Sinus tachycardia / palpitations — expected, but uncomfortable for the awake patient
  • Hypotension — beta-2 vasodilation; usually responds to slowing infusion and fluids
  • Myocardial ischemia — increased demand + dropped diastolic pressure; chest pain or ST changes mean stop
  • Tremor, anxiety, headache in awake patients
  • Hypokalemia with prolonged use — drives K into cells
  • Pro-arrhythmia — the whole point sometimes, but watch for sustained VT or hemodynamically unstable rhythms

Contraindications and cautions

  • Active ischemia or recent ACS
  • Significant aortic stenosis or hypertrophic obstructive cardiomyopathy
  • Digitalis toxicity (already pro-arrhythmic)
  • Severe uncorrected hypovolemia

Reversal

There’s no specific reversal. Stop the infusion — most effects resolve within minutes. Refractory tachycardia or hypotension may need:

  • IV fluids
  • A short-acting beta-blocker (esmolol) if the patient stays tachy and symptomatic
  • Phenylephrine for pure alpha support if needed

Common pitfalls

  • Bag concentration error — double-check whenever a new tech mixes the bag.
  • Running Iso at high doses through a small peripheral that infiltrates.
  • Forgetting to stop the infusion before sheath pull and watching the heart race in recovery.
  • Calling the case “non-inducible” without an adequate Iso challenge.

Last reviewed by Dr. Colombowala on May 22, 2026.

Not medical advice. This page is educational. Your situation may differ — discuss it with Dr. Colombowala or your treating physician before making decisions.